Skip to main content

Danaparoid Pregnancy and Breastfeeding Warnings

Brand names: Orgaran

Danaparoid Pregnancy Warnings

One study reports on 2 successful full-term pregnancies with normal infants at birth. Cord blood from the infants revealed no anti-Xa activity, although the mothers demonstrated considerable activity. No bleeding problems were encountered. It does not appear that danaparoid crosses the placenta during the second and third trimesters.

Successful danaparoid treatment of heparin-induced thrombocytopenia was reported in a 25-year-old woman pregnant with twins. She was treated with subcutaneous danaparoid until the time of delivery without adverse fetal or maternal effects.

Danaparoid has been assigned to pregnancy category B by the FDA. Animal studies at doses 6 to 8 times the normal recommended human dose have not revealed evidence of fetotoxicity. There are no controlled data in human pregnancy. Danaparoid should only be given during pregnancy when need has been clearly established.

See references

Danaparoid Breastfeeding Warnings

There are no data on the excretion of danaparoid into human milk.

See references

References for pregnancy information

  1. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]. Thromb Haemost. 1993;70:554-61.
  2. Product Information. Orgaran (danaparoid). Organon. 2001;PROD.
  3. Gill J, Kovacs MJ. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy. Obstet Gynecol. 1997;90(4 Pt 2):648-50.

References for breastfeeding information

  1. Product Information. Orgaran (danaparoid). Organon. 2001;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.